Assessment of response to treatment of unresectable liver tumours with 90Y microspheres:: Value of FDG PET versus computed tomography

被引:67
作者
Szyszko, Teresa
AL-Nahhas, Adil
Canelo, Ruben
Habib, Nagy
Jiao, Long
Wasan, Harpreet
Pagou, Margarita
Tait, Paul
机构
[1] Hammersmith Hosp, Dept Nucl Med, London W12 0HS, England
[2] Hammersmith Hosp, Dept Surg, London W12 0HS, England
[3] Hammersmith Hosp, Dept Oncol, London W12 0HS, England
[4] Hammersmith Hosp, Dept Radiol, London W12 0HS, England
关键词
malignant liver tumours; Y-90; microspheres; FDG PET; response to therapy;
D O I
10.1097/MNM.0b013e328011453b
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction Selective internal radiation therapy (SIRT) with SIR spheres (Y-90 microspheres) is a treatment option for liver tumours in patients in whom other therapies are inappropriate or have failed. This study aims to assess the value of FDG PET in assessing the response to SIRT as compared to computed tomography (CT). Material and methods Twenty-one patients (11 F, 10 M; age range 40-75 years, mean, 58 years) received SIR spheres at the Hammersmith Hospital. One patient received two treatments. Most patients had colorectal metastases (n=10),while the others (n=11) had liver metastasis from different primaries. The mean administered dose was 1.9 GBq (range, 1.2-2.5 GBq). Follow-up was done with FDG PET and CT at 6 weeks, and 6-monthly thereafter. Pre-therapy and post-therapy CT and PET scans were assessed visually (RECIST criteria for CT) and semi-quantitative for PET using the standardized uptake value (SUV). Result Eighty-six percent of patients showed decreased PET activity at 6 weeks while only 13% showed a partial response in the size of tumour on CT scan. The mean pre-treatment SUV was 12.2 +/- 3.7 and the mean post-treatment SUV was 9.3 +/- 3.7 (P=0.01). CT imaging showed progressive disease in 27% patients and stable liver disease in 60% patients. Based on FDG PET results one patient had surgery for down-staged tumour. Conclusion FDG PET imaging is more sensitive than CT in the assessment of early response to SIR spheres, allowing clinicians to proceed with further therapeutic options.
引用
收藏
页码:15 / 20
页数:6
相关论文
共 16 条
[1]  
BIERNERT M, 2005, EUR J NUCL MED MOL I, V32, P778
[2]  
Coldwell D, 2006, ANN ONCOL, V17, P56
[3]  
Dancey JE, 2000, J NUCL MED, V41, P1673
[4]  
Goin J, 2003, WORLD J NUCL MED, V2, P216
[5]   Randomised trial of SIR-Spheres® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer [J].
Gray, B ;
Van Hazel, G ;
Hope, M ;
Burton, M ;
Moroz, P ;
Anderson, J ;
Gebski, V .
ANNALS OF ONCOLOGY, 2001, 12 (12) :1711-1720
[6]   90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver:: Response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging [J].
Lewandowski, RJ ;
Thurston, KG ;
Goin, JE ;
Wong, CYO ;
Gates, VL ;
Van Buskirk, M ;
Geschwind, JFH ;
Salem, R .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2005, 16 (12) :1641-1651
[7]   HEPATIC PARENCHYMAL CHANGES AFTER INTRAARTERIAL Y-90 THERAPY - CT FINDINGS [J].
MARN, CS ;
ANDREWS, JC ;
FRANCIS, IR ;
HOLLETT, MD ;
WALKER, SC ;
ENSMINGER, WD .
RADIOLOGY, 1993, 187 (01) :125-128
[8]   Yttrium-90 microsphere therapy for hepatic malignancy: Devices, indications, technical considerations, and potential complications [J].
Murthy, R ;
Nunez, R ;
Szklaruk, J ;
Erwin, W ;
Madoff, DC ;
Gupta, S ;
Ahrar, K ;
Wallace, MJ ;
Cohen, A ;
Coldwell, DM ;
Kennedy, AS ;
Hicks, ME .
RADIOGRAPHICS, 2005, 25 :S41-S56
[9]   Selective internal radiation therapy with SIR-Spheres® in patients with nonresectable liver tumors [J].
Pöpperl, G ;
Helmberger, T ;
Münzing, W ;
Schmid, R ;
Jacobs, TF ;
Tatsch, K .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (02) :200-208
[10]  
Stubbs RS, 2001, HEPATO-GASTROENTEROL, V48, P333